Two-phase radioimmunotherapy using bispecific monoclonal antibodies (bs MAbs).
Bosslet
K
K
Research Laboratories of Behringwerke AG, Marburg, F.R.G.
Hermentin
P
P
Kuhlmann
L
L
Steinstraesser
A
A
Seemann
G
G
Sedlacek
H H
HH
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000918:Antibody Specificity; D002272:Carcinoembryonic Antigen / Q000276:immunology; D006801:Humans; D051379:Mice; D009374:Neoplasms, Experimental / Q000276:immunology / Q000378:metabolism / Q000532:radiotherapy*; D004369:Pentetic Acid / Q000627:therapeutic use; D011878:Radiotherapy / Q000379:methods; D011955:Receptors, Drug / Q000096:biosynthesis / Q000276:immunology; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D002272:Carcinoembryonic Antigen; D011955:Receptors, Drug; D015021:Yttrium Radioisotopes; D004369:Pentetic Acid